Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbocisteine in Nonalcoholic Fatty Liver Disease
NCT06863376Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carbocisteine in non-alcoholic fatty liver disease (NAFLD), sponsored by Tanta University. Started Mar 2025; status: recruiting.
02
Drugs
carbocisteine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06863376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863376.